

MIRAGEN THERAPEUTICS, INC.  
Form 8-K  
March 27, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 27, 2018 (March 26, 2018)**

**MIRAGEN THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-36483**  
**(Commission**

**File Number)**

**47-1187261**  
**(IRS Employer**

**Identification No.)**

**6200 Lookout Rd.**

**Boulder, CO**  
**(Address of principal executive offices)**

**80301**  
**(Zip Code)**

**Registrant's telephone number, including area code: (720) 643-5200**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## Section 8 Other Events

### Item 8.01 Other Events.

On March 27, 2018, Miragen Therapeutics, Inc., a Delaware corporation (the *Company*), announced the initiation of a Phase 1 clinical trial of MRG-110 by Les Laboratoires Servier and Institut de Recherches Servier (collectively, *Servier*). MRG-110, one of the Company's product candidates, is an inhibitor of microRNA-92 and is being developed under the License and Collaboration Agreement between the Company and Servier for the treatment of heart failure and other ischemic disease. In the clinical trial, MRG-110 will be evaluated for safety and tolerability in a systemic dosing protocol. The Phase 1 clinical trial is planned to enroll 49 male subjects, aged 18 to 45. A copy of the press release announcing the initiation of the Phase 1 clinical trial of MRG-110 by Servier is filed herewith as Exhibit 99.1 and incorporated by reference herein.

## Section 9 Financial Statements and Exhibits

### Item 9.01 Financial Statements and Exhibits.

#### (d) Exhibits

#### Exhibit

Number	Exhibit Description
99.1	<u>Press release, dated March 27, 2018.</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Miragen Therapeutics, Inc.**

Date: March 27, 2018

By: /s/ Jason A. Leverone  
Jason A. Leverone  
Chief Financial Officer